Skip to content

Trial Summary

PICCOLO (IMGN853-0419) is a Phase 2 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Acronym:

PICCOLO

ACTRN/NCT /ethics:

NCT05041257

Scientific title:

Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Sponsor / Cooperative group:

ImmunoGen, Inc.

Trial & Patient Characteristics

Cancer TypeGynaecological
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexFemale
Tumour Stream -
Cancer StageLocally Advanced
Anticipated Start Date2021-08-31
Anticipated End Date2024-05-31

Participating Hospitals

HospitalBurnside Hospital
Clinical Trial CoordinatorDiana Caruso
Emaildcaruso@bunsidehospital.asn.au
Phone08 7074 2353
Principal InvestigatorProfessor Martin Oehler
Recruitment StatusRecruiting